MCID: VSC002
MIFTS: 58

Vascular Dementia

Categories: Mental diseases, Cardiovascular diseases

Aliases & Classifications for Vascular Dementia

MalaCards integrated aliases for Vascular Dementia:

Name: Vascular Dementia 12 14
Multi-Infarct Dementia 72 50 69
Dementia, Vascular 72 41 69
Dementia, Vascular, Susceptibility to 13
Dementia, Multi-Infarct 41
Multi Infarct Dementia 12
Multifocal Dementia 12
Dementia Vascular 51

Classifications:



Summaries for Vascular Dementia

NINDS : 50 Multi-infarct dementia (MID) is a common cause of memory loss in the elderly.  MID is caused by multiple strokes (disruption of blood flow to the brain).  Disruption of blood flow leads to damaged brain tissue.  Some of these strokes may occur without noticeable clinical symptoms. Doctors refer to these as “silent strokes.”  An individual having a silent stroke may not even know it is happening, but over time, as more areas of the brain are damaged and more small blood vessels are blocked, the symptoms of MID begin to appear.  MID can be diagnosed by an MRI or CT of the brain, along with a neurological examination. Symptoms include confusion or problems with short-term memory; wandering, or getting lost in familiar places; walking with rapid, shuffling steps; losing bladder or bowel control; laughing or crying inappropriately; having difficulty following instructions; and having problems counting money and making monetary transactions.  MID, which typically begins between the ages of 60 and 75, affects men more often than women. Because the symptoms of MID are so similar to Alzheimer’s disease, it can be difficult for a doctor to make a firm diagnosis.  Since the diseases often occur together, making a single diagnosis of one or the other is even more problematic. 

MalaCards based summary : Vascular Dementia, also known as multi-infarct dementia, is related to binswanger's disease and dementia. An important gene associated with Vascular Dementia is APOE (Apolipoprotein E), and among its related pathways/superpathways are Neuroscience and Copper homeostasis. The drugs Dopamine and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are homeostasis/metabolism and behavior/neurological

Disease Ontology : 12 A dementia that involves impairments in cognitive function caused by problems in blood vessels that feed the brain.

Wikipedia : 72 Vascular dementia, also known as multi-infarct dementia (MID) and vascular cognitive impairment (VCI),... more...

Related Diseases for Vascular Dementia

Diseases related to Vascular Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
# Related Disease Score Top Affiliating Genes
1 binswanger's disease 31.5 ACHE APOE APP MAPT NOTCH3
2 dementia 31.1 ACHE APOE APP MAPT NOTCH3 PRNP
3 vascular disease 30.3 ACE APOE CST3 MTHFR PON1 VEGFA
4 ischemia 29.7 ACE APP PON1 VEGFA
5 speech and communication disorders 29.7 APOE MAPT PSEN1
6 hydrocephalus 29.3 APOE APP MAPT MBP
7 alzheimer disease 29.3 ACE ACHE APOE APP BCHE CHAT
8 cerebrovascular disease 29.3 ACE ACHE APOE APP MTHFR NOTCH3
9 arteries, anomalies of 29.2 ACE APOE MTHFR PON1 VEGFA
10 heart disease 29.1 ACE APOE CST3 MTHFR PON1
11 cerebral amyloid angiopathy, cst3-related 29.0 APOE APP CST3 MAPT PRNP PSEN1
12 dementia, lewy body 28.7 ACHE APOE APP BCHE MAPT PRNP
13 frontotemporal dementia 28.7 ACHE APOE APP BCHE MAPT PRNP
14 cerebral arteriosclerosis 11.0
15 subcortical arteriosclerotic encephalopathy 11.0
16 dementia - subcortical 10.8
17 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 10.8
18 moderate and severe traumatic brain injury 10.5 ACE APOE
19 posterior cortical atrophy 10.5 APOE MAPT
20 semantic dementia 10.4 APOE MAPT
21 generalized atherosclerosis 10.4 ACE APOE
22 alzheimer disease 4 10.4 APOE PSEN1
23 progressive non-fluent aphasia 10.4 MAPT PSEN1
24 cerebritis 10.4
25 genetic prion diseases 10.4 APOE PRNP
26 cerebral atherosclerosis 10.4 ACE APOE MTHFR
27 ischemic heart disease 10.4 ACE APOE MTHFR
28 behavioral variant of frontotemporal dementia 10.4 MAPT PSEN1
29 hemifacial spasm 10.3 MTHFR VEGFA
30 carotid stenosis 10.3 ACE APOE MTHFR
31 aortic atherosclerosis 10.3 ACE APOE PON1
32 dementia pugilistica 10.3
33 nominal aphasia 10.3 ACHE MAPT PSEN1
34 coronary stenosis 10.3 ACE APOE PON1
35 gait apraxia 10.3 APOE APP PSEN1
36 coronary heart disease 1 10.3 ACE APOE PON1
37 early-onset, autosomal dominant alzheimer disease 10.2 APP PSEN1
38 senile plaque formation 10.2 APOE APP CHAT
39 kluver-bucy syndrome 10.2 APP MAPT PSEN1
40 akinetic mutism 10.2 MAPT PRNP
41 early-onset familial alzheimer disease 10.2 APP MAPT PSEN1
42 amnestic disorder 10.2 ACHE CHAT PSEN1
43 aging 10.2
44 head injury 10.2 APOE CHAT
45 cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 10.2
46 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 10.2
47 leukoencephalopathy, hereditary diffuse, with spheroids 10.1 APP MAPT PRNP
48 coronary artery anomaly 10.1 ACE APOE MTHFR PON1
49 atherosclerosis susceptibility 10.1 ACE APOE PON1
50 acroosteolysis 10.1 RETREG1 VEGFA

Comorbidity relations with Vascular Dementia via Phenotypic Disease Network (PDN):


Acute Cystitis Cerebral Atherosclerosis
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Vascular Dementia:



Diseases related to Vascular Dementia

Symptoms & Phenotypes for Vascular Dementia

MGI Mouse Phenotypes related to Vascular Dementia:

43 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 ACE APP ACHE BCHE CHAT APOE
2 behavior/neurological MP:0005386 10.31 ACE APP ACHE CHAT APOE MBP
3 growth/size/body region MP:0005378 10.29 APOE ACE APP ACHE CHAT MBP
4 mortality/aging MP:0010768 10.25 ACE APP ACHE BCHE CHAT APOE
5 cardiovascular system MP:0005385 10.22 CHAT APOE ACE APP CST3 MAPT
6 hematopoietic system MP:0005397 10.19 APOE ACE APP ACHE MBP MAPT
7 nervous system MP:0003631 10.13 APP ACHE CHAT APOE PRNP MTHFR
8 integument MP:0010771 10.11 APP APOE MTHFR MAPT NOTCH3 PRNP
9 muscle MP:0005369 10.07 APP ACHE CHAT APOE PRNP CST3
10 limbs/digits/tail MP:0005371 9.91 CHAT APOE MTHFR PRNP VEGFA PSEN1
11 no phenotypic analysis MP:0003012 9.8 APOE APP ACHE MTHFR MAPT PRNP
12 reproductive system MP:0005389 9.77 ACE APP ACHE BCHE CHAT APOE
13 normal MP:0002873 9.76 CHAT APP MBP MAPT NOTCH3 PRNP
14 vision/eye MP:0005391 9.32 ACHE CHAT APOE PRNP MTHFR MAPT

Drugs & Therapeutics for Vascular Dementia

Drugs for Vascular Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 175)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
2
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1 120014-06-4 3152
3
Memantine Approved, Investigational Phase 4 19982-08-2 4054
4
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
5
Citalopram Approved Phase 4 59729-33-8 2771
6
Menthol Approved Phase 4,Phase 2,Phase 3 2216-51-5 16666
7
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
8
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
9
Galantamine Approved Phase 4,Phase 3,Phase 2 357-70-0 9651
10 Piracetam Approved, Investigational Phase 4 7491-74-9
11
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
12
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 644073 40400
13
Nicergoline Approved, Investigational Phase 4 27848-84-6 34040
14
Corticosterone Experimental Phase 4 50-22-6 5753
15
Serotonin Phase 4,Phase 3 50-67-9 5202
16 calcium channel blockers Phase 4,Phase 2,Phase 3
17 Serotonin Agents Phase 4,Phase 3
18 Serotonin Uptake Inhibitors Phase 4
19 Muscarinic Antagonists Phase 4
20 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Cholinergic Antagonists Phase 4
22 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
23 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3
25 Nootropic Agents Phase 4,Phase 3,Phase 2,Phase 1
26 Vasodilator Agents Phase 4,Phase 2,Phase 3
27 Parasympatholytics Phase 4
28 Dopamine Agents Phase 4,Phase 3,Phase 2
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
30 Antidepressive Agents Phase 4
31 Antidepressive Agents, Second-Generation Phase 4
32 Phosphodiesterase Inhibitors Phase 4,Phase 2
33 Antihypertensive Agents Phase 4,Phase 2,Phase 3
34 Excitatory Amino Acid Antagonists Phase 4
35 Excitatory Amino Acids Phase 4
36 Psychotropic Drugs Phase 4,Phase 3,Phase 2
37 Autonomic Agents Phase 4,Phase 3,Phase 2
38 Antiparkinson Agents Phase 4,Phase 3
39 Calcium, Dietary Phase 4,Phase 2,Phase 3
40 Cerebrolysin Phase 4
41 Analgesics Phase 4,Phase 2
42 Respiratory System Agents Phase 4
43 Fibrinolytic Agents Phase 4
44 Central Nervous System Depressants Phase 4,Phase 3
45 Adrenergic Agents Phase 4,Phase 3,Phase 2
46 Adrenergic alpha-Antagonists Phase 4,Phase 2
47 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
48 Narcotic Antagonists Phase 4
49 Narcotics Phase 4
50 Neuroprotective Agents Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 100)

# Name Status NCT ID Phase Drugs
1 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
2 Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:A Randomized Controlled Trial Unknown status NCT00196703 Phase 4 memantine
3 Atrial Fibrillation and the Risk for Neurological Complications Unknown status NCT00357227 Phase 4
4 Efficacy and Safety Study of Nimodipine to Prevent Mild Cognitive Impairment After Acute Ischemic Strokes Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
5 Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
6 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4 Cilostazol;Aspirin
7 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
8 Memantine and Intensive Speech-Language Therapy in Aphasia Completed NCT00640198 Phase 4 memantine;memantine;placebo
9 Efficacy of Pain Treatment on Depression in Patients With Dementia Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
10 Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine Completed NCT01009476 Phase 4 Galantamine;Nootropics (ginkgo biloba, nicergoline, piracetam, or others)
11 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
12 Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Unknown status NCT02453932 Phase 3 Tianzhi granule and placebo identified to donepezil;Donepezil and placebo identified to Tianzhi granule;Placebo
13 Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00130338 Phase 3 Rivastigmine
14 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00099216 Phase 3 Rivastigmine
15 A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia Completed NCT00261573 Phase 3 galantamine hydrobromide
16 A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia Completed NCT00035191 Phase 3 galantamine
17 Seroquel- Agitation Associated With Dementia Completed NCT00621647 Phase 3 Quetiapine Fumarate;Quetiapine Fumarate;Placebo
18 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249158 Phase 3 Risperidone
19 Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome Completed NCT02778776 Phase 3 Metformin
20 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3 DatSCAN
21 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249145 Phase 3 risperidone
22 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00253123 Phase 3 risperidone
23 Symptomatic Treatment of Vascular Cognitive Impairment Recruiting NCT02098824 Phase 2, Phase 3 Galantamine;Methylphenidate;Placebo
24 Risk Reduction for Alzheimer's Disease Recruiting NCT02913664 Phase 2, Phase 3 Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine);Atorvastatin
25 MIND Diet Intervention and Cognitive Decline Recruiting NCT02817074 Phase 3
26 Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis Recruiting NCT03325556 Phase 3 Placebo;Pimavanserin 34 mg;Pimavanserin 20 mg
27 Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function Recruiting NCT03082014 Phase 3 Amlodipine;Losartan;Atenolol
28 Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia Unknown status NCT01761227 Phase 2 Fufangdanshen Tablets;Placebo
29 The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule Unknown status NCT01978730 Phase 2 high dose group of SaiLuoTong capsule;low dose group of SaiLuoTong;the control group
30 Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity Unknown status NCT01466543 Phase 2 Zydena (Udenafil);Placebo
31 Safety Study of Dabigatran in CADASIL Unknown status NCT01361763 Phase 2 Dabigatran;Antiplatelets
32 Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) Completed NCT01475578 Phase 2 STA-1;Ergoloid Mesylates tablet
33 Effect of Insulin Sensitizer Metformin on AD Biomarkers Completed NCT01965756 Phase 2 Metformin;Placebos
34 DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia Completed NCT02103673 Phase 2 DAOIB;Placebo
35 Oxidative Stress and Nutritional Supplementation Intervention Study Completed NCT01234506 Phase 2
36 Delta-THC in Dementia Completed NCT01608217 Phase 2 delta-9-tetrahydrocannabinol (delta-THC);Placebo;Acetaminophen;Acetaminophen
37 The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment Completed NCT00103948 Phase 2 Aricept
38 A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia Recruiting NCT02886494 Phase 2 BAC;Matched placebo
39 n-3 PUFA for Vascular Cognitive Aging Active, not recruiting NCT01953705 Phase 2 Omega 3 PUFA;Placebo
40 Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia Not yet recruiting NCT03230071 Phase 2 TMBCZG
41 BAC in Patient With Alzheimer's Disease or Vascular Dementia Not yet recruiting NCT02467413 Phase 2 BAC
42 Aricept to Improve Functional Tasks in Vascular Dementia Unknown status NCT00457769 Phase 1 Donepezil;Donepezil
43 Hyperbaric Oxygen Therapy for Mild Cognitive Impairment Unknown status NCT02085330
44 MRS and DTI of White Matter in Alzheimer's Disease Unknown status NCT00172900
45 Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 (Follow-up Studie) Unknown status NCT01126775
46 Efficiency Study of Siwu Tang to Treat Brain Hypoperfusion Syndrome Unknown status NCT01221662 Siwu Tang
47 Memantine on Aggression and Agitation of Alzheimer's Disease (AD) Unknown status NCT00703430 Memantine
48 Cognition and Affect After Stroke: a Prospective Evaluation of Risks Unknown status NCT02585349
49 Dementia Phenotypes in Primary Care, Hospital, and National Mortality Registries Unknown status NCT02549872
50 Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Unknown status NCT02071784

Search NIH Clinical Center for Vascular Dementia

Cochrane evidence based reviews: dementia, vascular

Genetic Tests for Vascular Dementia

Anatomical Context for Vascular Dementia

MalaCards organs/tissues related to Vascular Dementia:

38
Brain, Testes, Cortex, Heart, Eye, Prostate, Bone

Publications for Vascular Dementia

Articles related to Vascular Dementia:

(show top 50) (show all 781)
# Title Authors Year
1
Mitochondrial factor and cell cytokines associate with TCM syndrome scale in vascular dementia patients. ( 29375680 )
2018
2
Predicting outcome of Morris water maze test in vascular dementia mouse model with deep learning. ( 29415035 )
2018
3
Acupuncture Prevents the Impairment of Hippocampal LTP Through I^1-AR in Vascular Dementia Rats. ( 29435917 )
2018
4
Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer's and Vascular Dementia Drugs. ( 29401682 )
2018
5
Albuminuria Increases the Risks for Both Alzheimer Disease and Vascular Dementia in Community-Dwelling Japanese Elderly: The Hisayama Study. ( 29353232 )
2018
6
Ligustrazine suppresses neuron apoptosis via the Bax/Bcl-2 and caspase-3 pathway in PC12 cells and in rats with vascular dementia. ( 29247598 )
2018
7
Nanotherapy for Alzheimer's disease and vascular dementia: Targeting senile endothelium. ( 29274774 )
2018
8
Vascular dementia: clinicopathologic and genetic considerations. ( 29380913 )
2018
9
Cognitive impairment in Parkinson's disease, Alzheimer's dementia, and vascular dementia: the role of the clock-drawing test. ( 29417704 )
2018
10
Chinese Herbal Medicine for Vascular Dementia: A Systematic Review and Meta-Analysis of High-Quality Randomized Controlled Trials. ( 29439346 )
2018
11
Repeated administration of Sailuotong, a fixed combination of Panax ginseng, Ginkgo biloba, and Crocus sativus extracts for vascular dementia, alters CYP450 activities in rats. ( 29425645 )
2018
12
Effect of Telmisartan on Preventing Learning and Memory Deficits Via Peroxisome Proliferator-Activated Receptor-I^ in Vascular Dementia Spontaneously Hypertensive Rats. ( 29241675 )
2018
13
Neuroprotective effect of berberine chloride on cognitive impairment and hippocampal damage in experimental model of vascular dementia. ( 29372037 )
2018
14
Puerarin up-regulates methyl-CpG binding protein 2 phosphorylation in hippocampus of vascular dementia rats. ( 29327124 )
2018
15
Correlations between Gray Matter and White Matter Degeneration in Pure Alzheimer's Disease, Pure Subcortical Vascular Dementia, and Mixed Dementia. ( 28842654 )
2017
16
Low serum insulin-like growth factor-I (IGF-I) level is associated with increased risk of vascular dementia. ( 28963885 )
2017
17
Neuropsychological Profiles Differentiate Alzheimer Disease from Subcortical Ischemic Vascular Dementia in an Autopsy-Defined Cohort. ( 28595184 )
2017
18
Resveratrol loaded solid lipid nanoparticles attenuate mitochondrial oxidative stress in vascular dementia by activating Nrf2/HO-1 pathway. ( 28782592 )
2017
19
Can MRI water apparent diffusion coefficient (ADC) value discriminate between idiopathic normal pressure hydrocephalus, Alzheimer's disease and subcortical vascular dementia? ( 28923529 )
2017
20
Vitamin D, Homocysteine, and Folate in Subcortical Vascular Dementia and Alzheimer Dementia. ( 28611659 )
2017
21
Anti-Inflammatory and Neuroprotective Effects of Co-UltraPEALut in a Mouse Model of Vascular Dementia. ( 28634464 )
2017
22
The pathology and pathophysiology of vascular dementia. ( 29273521 )
2017
23
Strategic infarcts of the thalamus: an uncommon cause of vascular dementia. ( 28571959 )
2017
24
Synergistic effect of tanshinone IIA and mesenchymal stem cells on preventing learning and memory deficits via anti-apoptosis, attenuating tau phosphorylation and enhancing the activity of central cholinergic system in vascular dementia. ( 27845241 )
2017
25
Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia. ( 27901381 )
2017
26
Effect of hippocampal La89NBP on BDNF and TrkB expression and neurological function of vascular dementia rats. ( 28944854 )
2017
27
Effect of glycosides of Cistanche on the expression of mitochondrial precursor protein and keratin type II cytoskeletal 6A in a rat model of vascular dementia. ( 28852399 )
2017
28
Effect of Endogenous Arginine-Vasopressin Arising from the Paraventricular Nucleus on Learning and Memory Functions in Vascular Dementia Model Rats. ( 29333438 )
2017
29
Circulating microRNAs as potential biomarkers for the identification of vascular dementia due to cerebral small vessel disease. ( 28633305 )
2017
30
Astrocyte-derived lipocalin-2 mediates hippocampal damage and cognitive deficits in experimental models of vascular dementia. ( 28581123 )
2017
31
Cerebral gray matter volume reduction in subcortical vascular mild cognitive impairment patients and subcortical vascular dementia patients, and its relation with cognitive deficits. ( 28828207 )
2017
32
Acupuncture for patients with vascular dementia: a systematic review protocol. ( 29217728 )
2017
33
Hypercholesterolaemia and vascular dementia. ( 28667059 )
2017
34
Serum homocysteine levels in patients with probable vascular dementia. ( 28786967 )
2017
35
White matter damage and glymphatic dysfunction in a model of vascular dementia in rats with no prior vascular pathologies. ( 27940353 )
2017
36
Vascular parkinsonism and vascular dementia are associated with an increased risk of vascular events or death. ( 28905043 )
2017
37
Observational study of vascular dementia in the Spanish elderly population according to type 2 diabetes status: trends in incidence, characteristics and outcomes (2004-2013). ( 28780555 )
2017
38
Color vision test to differentiate Alzheimer's disease from vascular dementia. ( 28625199 )
2017
39
Evolution of short cognitive test performance in stroke patients with vascular cognitive impairment and vascular dementia: Baseline evaluation and follow-up. ( 29354218 )
2017
40
Association of genetic polymorphisms of claudin-1 with small vessel vascular dementia. ( 28273404 )
2017
41
N-Terminal Prosomatostatin and Risk of Vascular Dementia. ( 28854435 )
2017
42
Edaravone injection reverses learning and memory deficits in a rat model of vascular dementia. ( 27864280 )
2017
43
Environmental Enrichment Improves Spatial Learning and Memory in Vascular Dementia Rats with Activation of Wnt/I^-Catenin Signal Pathway. ( 28082734 )
2017
44
Vitamin B6 prevents isocarbophos-induced vascular dementia in rats through N-methyl-D-aspartate receptor signaling. ( 28872356 )
2017
45
Prevention of hypertension-induced vascular dementia by Lactobacillus paracasei subsp. paracasei NTU 101-fermented products. ( 27937042 )
2017
46
Correlation study of Framingham risk score and vascular dementia: An observational study. ( 29390252 )
2017
47
Efficacy of cognitive stimulation therapy for older adults with vascular dementia. ( 29354225 )
2017
48
Selective modulator of cannabinoid receptor type 2 (CB2) against biochemical alterations and brain damage in chronic cerebral hypoperfusion induced vascular dementia. ( 27599483 )
2016
49
Neuroprotection against vascular dementia after acupuncture combined with donepezil hydrochloride: P300 event related potential. ( 27127486 )
2016
50
Astroglial NF-kB contributes to white matter damage and cognitive impairment in a mouse model of vascular dementia. ( 27487766 )
2016

Variations for Vascular Dementia

Expression for Vascular Dementia

Search GEO for disease gene expression data for Vascular Dementia.

Pathways for Vascular Dementia

GO Terms for Vascular Dementia

Cellular components related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.88 ACHE APP PRNP PSEN1 VEGFA
2 axon GO:0030424 9.81 APP CST3 MAPT PSEN1
3 endoplasmic reticulum lumen GO:0005788 9.8 APOE APP BCHE CST3
4 growth cone GO:0030426 9.7 APP MAPT PSEN1
5 extracellular region GO:0005576 9.65 ACE ACHE APOE APP BCHE CST3
6 blood microparticle GO:0072562 9.62 APOE BCHE PON1 SERPINA3
7 neuronal cell body GO:0043025 9.55 APOE CST3 MAPT MBP PSEN1
8 platelet alpha granule lumen GO:0031093 9.54 APP SERPINA3 VEGFA
9 amyloid-beta complex GO:0106003 9.46 APOE PRNP
10 ciliary rootlet GO:0035253 9.43 APP PSEN1
11 neuromuscular junction GO:0031594 9.43 ACHE APP PSEN1
12 nuclear envelope lumen GO:0005641 9.4 APP BCHE
13 extracellular space GO:0005615 9.28 ACE ACHE APOE APP BCHE CST3

Biological processes related to Vascular Dementia according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.88 APOE APP CST3 PSEN1
2 negative regulation of endopeptidase activity GO:0010951 9.83 APP CST3 SERPINA3
3 negative regulation of peptidase activity GO:0010466 9.83 APP CST3 SERPINA3
4 platelet degranulation GO:0002576 9.83 APP SERPINA3 VEGFA
5 Notch signaling pathway GO:0007219 9.82 APP NOTCH3 PSEN1
6 response to toxic substance GO:0009636 9.81 CST3 MBP PON1
7 cholesterol metabolic process GO:0008203 9.78 APOE APP PON1
8 response to oxidative stress GO:0006979 9.77 APOE APP CST3 PRNP PSEN1
9 forebrain development GO:0030900 9.76 APP NOTCH3 PSEN1
10 learning or memory GO:0007611 9.73 APP PRNP PSEN1
11 synapse organization GO:0050808 9.7 APP MAPT PSEN1
12 cellular response to amyloid-beta GO:1904646 9.65 APP PRNP PSEN1
13 Notch receptor processing GO:0007220 9.64 NOTCH3 PSEN1
14 positive regulation of cholesterol efflux GO:0010875 9.63 APOE PON1
15 amyloid-beta metabolic process GO:0050435 9.63 ACE PSEN1
16 neurotransmitter biosynthetic process GO:0042136 9.62 ACHE CHAT
17 supramolecular fiber organization GO:0097435 9.62 CST3 MAPT
18 cellular copper ion homeostasis GO:0006878 9.61 APP PRNP
19 artery morphogenesis GO:0048844 9.61 APOE NOTCH3 VEGFA
20 response to folic acid GO:0051593 9.6 BCHE MTHFR
21 amyloid fibril formation GO:1990000 9.59 APP MAPT
22 amyloid precursor protein metabolic process GO:0042982 9.58 ACHE APOE PSEN1
23 negative regulation of amyloid-beta formation GO:1902430 9.57 APOE PRNP
24 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.55 ACE VEGFA
25 regulation of epidermal growth factor-activated receptor activity GO:0007176 9.54 APP PSEN1
26 astrocyte activation involved in immune response GO:0002265 9.51 APP PSEN1
27 astrocyte activation GO:0048143 9.5 APP MAPT PSEN1
28 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.49 APP PSEN1
29 smooth endoplasmic reticulum calcium ion homeostasis GO:0051563 9.46 APP PSEN1
30 negative regulation of long-term synaptic potentiation GO:1900272 9.43 APOE APP PRNP
31 modulation of age-related behavioral decline GO:0090647 9.33 APP PRNP PSEN1
32 neuron projection maintenance GO:1990535 9.13 APP PRNP PSEN1
33 positive regulation of amyloid fibril formation GO:1905908 8.8 APOE APP PSEN1

Molecular functions related to Vascular Dementia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase inhibitor activity GO:0030414 9.58 APP CST3 SERPINA3
2 identical protein binding GO:0042802 9.56 APOE APP BCHE CST3 MAPT NOTCH3
3 protease binding GO:0002020 9.54 CST3 MBP PRNP
4 lipoprotein particle binding GO:0071813 9.32 APOE MAPT
5 cholinesterase activity GO:0004104 9.26 ACHE BCHE
6 acetylcholinesterase activity GO:0003990 9.16 ACHE BCHE
7 amyloid-beta binding GO:0001540 9.02 ACHE APOE BCHE CST3 PRNP

Sources for Vascular Dementia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....